Second quarter growth at Trinity Biotech

NASDAQ-listed biotechnology group Trinity Biotech has reported a strong set of results for the second quarter of the year, with after-tax profits more than doubling to $1.1 million while earnings per share were 77 per cent higher than the same period last year, at 3.9 cents. Sales grew 18 per cent to $6.5 million while operating profits for the quarter jumped from $598,000 to $1.26 million with operating margins improving from 32 per cent to 43 per cent. Profits for the six months to the end of June doubled to $2 million.